Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

Boyd MA, Boffito M, Castagna A, Estrada V. HIV Med. 2019;20(suppl 1):3-11.

Pharmacist-driven rapid ART reduces time to virologic suppression in Rhode Island.

Brotherton AL, Shah RB, Garland J, et al. 27th Conference on Retroviruses and Opportunistic Infections (CROI) 2020; March 8-11, 2020; Boston, MA. Abstract 498.

RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.

Coffey S, Bacchetti P, Sachdev D, et al. AIDS. 2019;33(5):825-832.

A rapid entry program in the South: improving access to care and time to viral suppression.

Colasanti J, Sumitani J, Mehta CC, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI) 2018; March 4−7, 2018; Boston, MA. Abstract 1109.

Assessing the Efficacy and Feasibility of a Retail Pharmacy-Based HIV Testing Program.

Collins BC, Bronson HW, Martin EG. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018;5(7):e347-e356.

HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.

Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019;170:104543.

Benefits and risks of rapid initiation of antiretroviral therapy.

Ford N, Migone C, Calmy A. et al. AIDS. 2018;32:17-23.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, et al. Lancet HIV. 2016;3(4):e158-e165.

Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 week results of the NEAT022 study.

Gatell JM, Assoumou L, Moyle G, et al. Clin Infect Dis. 2019;68(4):597-606.

Determination of optimized multidisciplinary care team for maximal antiretrovial therapy adherence.

Horberg MA, Hurley LB, Towner WJ, et al. J Acquir Immune Defic Syndr. 2012; 60(2):183-190.

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans.

Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis.

Kong AM, Pozen A, Anastos K, et al. AIDS Pt Care STDS. 2019;33(3);93-103.

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.

Lee SS, Havens JP, Sayles HR, et al. BMC Infect Dis. 2018;18(1):310.

A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients.

McNicholl IR, Gandhi M, Hare CB, et al. Pharmacotherapy. 2017;37(12):1498-1506.

Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States.

Mizuno Y, Beer L, Huang P, Frazier EL. LGBT Health. 2017;4(3):181-187.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.

Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.

Penn C, Watermeyer J, Evans M. Patient Educ Couns. 2011;83(3):310-318.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients.

Rossetti B, Montagnani F, De Luca A. Expert Opin Pharmacother. 2018;19(7):713-738.

Interdisciplinary care team with pharmacist in a community-based HIV clinic.

Samuel O, Unonu JM, Dotson K, et al. J Natl Med Assoc. 2018;110(4):378-383.

Trends in the San Francisco human immunodeficiency virus epidemic in the "Getting to Zero" era.

Scheer S, Hsu L, Schwarcz S, et al. Clin Infect Dis. 2018;66(7):1027-1034.

Switching antiretroviral regimes for the treatment of HIV: safety implications.

Utrillo L, Vidal F, Puig T, Domingo P. Expert Opin Drug Saf. 2016;15(10):1349-1360.

HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Weidle PJ, Lecher S, Botts LW, et al. J Am Pharm Assoc. 2014; 54(5):486-492.